By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Liver Diseases and Conditions - Hepatitis C Virus are discussed in a new report. According to news reporting out of Taipei, Taiwan, by NewsRx editors, research stated, “Hepatocarcinogenicity of aflatoxin B-1 (AFB(1)) has rarely been studied in populations with hepatitis C virus (HCV) infection and those without hepatitis B virus (HBV) and HCV infection (non-B-non-C). This case-control study nested in a communitybased cohort aimed to investigate the HCC risk associated with AFB(1) in HCV-infected and non-B-non-C participants.”
Our news journalists obtained a quote from the research from Genomic Research Center, “Baseline serum AFB(1)-albumin adduct levels were measured in 100 HCC cases and 1767 controls seronegative for anti-HCV and HBsAg (non-B-non-C), and another 103 HCC cases and 176 controls who were anti-HCV-seropositive and HBsAg-seronegative. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were estimated using logistic regression. In 20 years of follow-up, the follow-up time to newly developed HCC was significantly shorter in participants with higher serum AFB(1)-albumin adduct levels in non-B-nonC (p = 0.0162) and HCV-infected participants (p < 0.0001). Within 8 years of follow-up, HCV infection and AFB(1) exposure were independent risk factors for HCC. Elevated serum AFB(1)-albumin adduct levels were significantly associated with an increased risk of HCC newly developed within 8 years of follow-up in non-B-non-C participants with habitual alcohol consumption [crude OR (95% CI) for high vs. low/undetectable levels, 4.22 (1.16-15.37)] and HCV-infected participants [3.39 (1.31-8.77)], but not in non-B-non-C participants without alcohol drinking habit. AFB(1) exposure remained an independent risk predictor for HCV-related HCC after adjustment for other HCC predictors (multivariate-adjusted OR [95% CI], 3.65 [1.32-10.10]).”
According to the news editors, the research concluded: “AFB1 exposure contributes to the development of HCC in participants with significant risk factors for cirrhosis including alcohol and HCV infection.”
For more information on this research see: Aflatoxin B-1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption. European Journal of Cancer , 2018;94():37-46. European Journal of Cancer can be contacted at: Elsevier Sci Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, Oxon, England. (Elsevier - www.elsevier.com; European Journal of Cancer - http://www.journals.elsevier.com/european-journal-of-cancer/)
Our news journalists report that additional information may be obtained by contacting Y.J. Chu, Academy Sinica, Genom Res Center, Taipei 115, Taiwan. Additional authors for this research include H.I. Yang, H.C. Wu, M.H. Lee, J. Liu, L.Y. Wang, S.N. Lu, C.L. Jen, S.L. You, R.M. Santella and C.J. Chen.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
CITATION: (2018-05-01), Findings on Hepatitis C Virus Discussed by Investigators at Genomic Research Center (Aflatoxin B-1 exposure increases the risk of hepatocellular carcinoma associated with hepatitis C virus infection or alcohol consumption), Cancer Weekly, 301, ISSN: 1532-4567, BUTTER® ID: 015572935
From the newsletter Cancer Weekly.
https://www.newsrx.com/Butter/#!Search:a=15572935
This is a NewsRx® article created by NewsRx® and posted by NewsRx®. As proof that we are NewsRx® posting NewsRx® content, we have added a link to this steemit page on our main corporate website. The link is at the bottom left under "site links" at https://www.newsrx.com/NewsRxCorp/.
We have been in business for more than 20 years and our full contact information is available on our main corporate website.
We only upvote our posts after at least one other user has upvoted the article to increase the curation awards of upvoters.
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.